UK markets close in 15 minutes
  • FTSE 100

    7,474.70
    +2.53 (+0.03%)
     
  • FTSE 250

    18,916.20
    +92.19 (+0.49%)
     
  • AIM

    833.58
    -0.83 (-0.10%)
     
  • GBP/EUR

    1.1659
    +0.0076 (+0.66%)
     
  • GBP/USD

    1.2292
    +0.0054 (+0.44%)
     
  • BTC-GBP

    13,986.51
    +149.94 (+1.08%)
     
  • CMC Crypto 200

    404.91
    -1.34 (-0.33%)
     
  • S&P 500

    3,964.54
    +1.03 (+0.03%)
     
  • DOW

    33,737.31
    -44.17 (-0.13%)
     
  • CRUDE OIL

    72.74
    +1.28 (+1.79%)
     
  • GOLD FUTURES

    1,809.60
    +8.10 (+0.45%)
     
  • NIKKEI 225

    27,901.01
    +326.58 (+1.18%)
     
  • HANG SENG

    19,900.87
    +450.64 (+2.32%)
     
  • DAX

    14,359.72
    +95.16 (+0.67%)
     
  • CAC 40

    6,666.54
    +19.23 (+0.29%)
     

Senseonics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

GERMANTOWN, Md., September 07, 2022--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Management is scheduled to participate on Tuesday, September 13, 2022, at 7:20 am ET and will hold one-on-one meetings following. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company’s website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907006085/en/

Contacts

Senseonics Investor Relations:
Philip Taylor
Investor Relations
415-937-5406
Investors@senseonics.com